Related Experiment Video

Updated: Aug 17, 2025

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
08:20

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

20.6K

The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials

Jia Peng1, Shucai Yang2, Calvin S H Ng1

  • 1Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.

Pharmacology & Therapeutics
|December 17, 2022
PubMed

Insights

Forkhead box protein P3 (FOXP3) shows abnormal expression in non-small cell lung cancer (NSCLC). This review explores FOXP3

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality despite treatment advancements.
  • Forkhead box protein P3 (FOXP3), a key regulator of regulatory T cells (Tregs), is aberrantly expressed in various tumor cells, including lung cancer.
  • Emerging evidence suggests a carcinogenic role for FOXP3 in lung cancer development and progression.

Purpose of the Study:

  • To review the multifaceted functions of FOXP3 in the context of NSCLC.
  • To analyze the regulatory mechanisms governing FOXP3 expression in lung cancer.
  • To explore the therapeutic potential of targeting FOXP3 for novel NSCLC treatments.

Main Methods:

  • Comprehensive literature review of studies investigating FOXP3 in NSCLC.
  • Analysis of existing data on FOXP3 expression patterns and functional roles.
  • Synthesis of information regarding FOXP3 regulation and its implications for therapy.

Main Results:

  • FOXP3 expression is dysregulated in NSCLC tumoral cells.
  • FOXP3 exhibits a pro-tumorigenic effect in lung cancer.
  • Understanding FOXP3's function and regulation is crucial for NSCLC research.

Conclusions:

  • FOXP3 represents a significant molecular target for NSCLC intervention.
  • Targeting FOXP3 may offer a novel therapeutic strategy for NSCLC patients.
  • Further research into FOXP3's role can accelerate the development of effective NSCLC treatments.
Keywords:
FOXP3NSCLCOncogeneTherapeutic target

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K